Cannabis-based gel (Zygel) for Fragile X syndrome fails to meet study’s primary endpoint

In study (n=212), this experimental cannabis-based gel was not statistically significant in improving aberrant behaviour when compared to a placebo in patients with this rare neurological disorder characterised by mild-to-moderate intellectual disability.

Source:

Reuters Health